Novartis Ag

Morphosys Ag

Ute Jaeger

Michael Roguska

Barbara Brannetti

Michael Tesar

Igor Splawski

Joy Gispati Ghosh

Michael Stefanidakis

Christian Carsten Silvester Kunz

Yong-In Kim

Sha-Mei Liao

Leslie Ngozi Anuna Johnson

Christoph Heusser

Michael Otto Bardroff

Jose M Carballido Herrera

Christoph Schwaerzler

Daniela Della Ducata

The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).

Nucleic acids encoding anti-Factor P antibodies

The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38

Compositions comprising antibodies targeting factor P

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

Anti-CD38 human antibodies and uses thereof

The present invention provides methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Generation and profiling of fully human HuCAL gold&#xae;-derived therapeutic antibodies specific for human CD3i

Antibodies that bind factor P

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R&#x3b2;2 chain) as well as IL23 receptor (together with IL23R&#x3b1; chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN&#x3b3; production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Therapeutic antibodies binding IL12R&#x3b2;1

Growing community of inventors

Munich, Germany

Ute Jaeger